alnylam
Alnylam is seeking a Principal Associate Scientist to validate therapeutic gene targets through in vitro and in vivo mechanistic studies to support the discovery of RNAi medicines. The role involves performing preclinical research, developing new assays, and contributing to internal decision-making across various therapeutic areas. This position requires strong technical expertise in biochemistry and molecular biology within a multidisciplinary team.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
13% below the average for this role
Senior Research Associate, In Vivo Pharmacology
Arbor Biotechnologies
Research Associate, Discovery Biology
Assembly Bio
Senior Research Associate, In Vivo Discovery
Pivotal
Associate Scientist
ImmunEdge, Inc
(StealthCo) Scientist: Biology and Cell Pharmacology
Foresite Labs
Senior Scientist (In Vitro/Ex Vivo Assay Specialist)
Calico